Pharmacokinetics of F105, a human monoclonal antibody, in persons infected with human immunodeficiency virus type 1

Clinical Pharmacology and Therapeutics

Volumn 59, Issue 6, 1996, Pages 662-667

  Wolfe, Erika J ^b   Cavacini, Lisa A ^b   Samore, Matthew H ^b   Posner, Marshall R ^b   Kozial, Carolyn ^b   Spino, Cathie ^b   Trapnell, Carol Braun ^b   Ketter, Nzeera ^b   Hammer, Scott ^b   Gambertoglio, John G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

F 105; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MALE; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTIBODIES, MONOCLONAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HALF-LIFE; HIV-1; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED;

EID: 15844378936     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)90006-5     Document Type: Article

References (13)

1. Cummins LM, Weinholf KJ, Matthews TJ, et al. Preparation and characterization of an intravenous solution of IgG from human immunodeficiency virusseropositive donors. Blood 1991;5:1111-7.
2. Posner MR, Cavacini LA, Emes CL, Power J, Byrn R. Neutralization of HIV-1 by F105, a human monoclonal antibody to the CD4 binding site of gp120. J Acquir Immune Defic Syndr 1993;6:7-14.
3. Posner MR, Hideshina T, Cannon T, Mukherjee M, Mayer KH, Byrn RA. An IgG human monoclonal antibody that reacts with HIV-1/gp120, inhibits virus binding to cells, and neutralizes infection. J Immunol 1991;146:4325-32.
4. Starcich BR, Hahn BH, Shaw GS, et al. Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS. Cell 1986;45:637-48.
5. Ho DD, Sarngadharan MG, Hirsch MS, et al. Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins. J Virol 1987;61:2024-8.
6. Robert-Guroff M, Goedert JJ, Naugle CJ, Jennings AM, Battner WA, Gallo RC. Spectrum of HIV-1 neutralizing antibodies in a cohort of homosexual men: results of a 6-year prospective study. AIDS Res Hum Retroviruses 1988;4:343-50.
7. Lu W, Ahih Wk, Tourani JM, Eme D, Alter HJ, Andrieu JM. Lack of isolate-specific neutralizing activity is correlated with an increased viral burden in rapidly progressing HIV-1 infected patients. AIDS 1993;7(suppl 2):S91-9.
8. Cavacini LA, Emes CL, Power J, et al. Loss of serum antibodies to a conformational epitope of HIV-1/ gp120 identified by a human monoclonal antibody is associated with disease progression. J Acquir Immune Defic Syndr 1993;6:1093-102.
9. Cavacini LA, Power J, Emes CL, Mace K, Treacy G, Posner MR. Plasma pharmacokinetics and biological activity of a human immunodefiency virus type 1 neutralizing human monoclonal antibody, F105, in cynomolgus monkeys. J Immunother Emphasis Tumor Immunol 1994;4:251-6.
10. Solomon A, Waldmann TA, Fhaey JL. Metabolism of normal 6.6S γ-globulin in normal subjects and in patients with macroglobulinemia and multiple myeloma. J Lab Clin Med 1963;62:1-17.
11. Morell A, Terry WD, Waldman TA. Metabolic properties of IgG subclasses in man. J Clin Invest 1970;49: 673-80.
12. Hinkula J, Gratt G, Gillan G, et al. Immunological and virological interaction in patients receiving passive immunotherapy with HIV-1 neutralizing antibodies. J Acquir Immune Defic Syndr 1994;7:940-51.
13. LoBuglioli AF, Wheeler RH, Trang J, et al. Mouse/ human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci USA 1989; 86:4220-4.